A weekly read on the gut, the brain, and the wiring in between. One clinical pearl, one paper, one product, one person. No hype, no selling, just the stuff I actually think about.
1. Practice
One broken gene, four organ systems, and the most useful sentence you can say before anesthesia.
In 2004, the year I graduated high school, a strange little trial ran in Anesthesiology. Ten natural redheads and ten dark-haired women, desflurane (an inhaled anesthetic) titrated against a standardized noxious stimulus, and the redheads needed nearly 20 percent more anesthetic to stop responding. Nine of the ten carried loss-of-function variants in a single gene, the melanocortin-1 receptor, MC1R (Liem et al., Anesthesiology 2004;101:279-283).
The follow-up landed a year later: subcutaneous lidocaine underperforms in redheads too. Which recasts a fact every dentist already knew and misfiled. Red-haired patients are about twice as likely to fear and avoid dental care, and for generations that went in the chart as nerves. It was pharmacology the whole time. They feel the drill because the drug is failing, not because their courage is.
Now the part that shouldn't make sense. These are the patients we cannot numb, and yet their baseline pain thresholds run higher, not lower. In 2021 the Fisher lab at Mass General worked out why: melanocytes with broken MC1R put out less of a hormone called alpha-MSH, and losing it tips the body's standing balance toward its own opioid tone. Mice carrying the redhead variant tolerate more before they flinch, and naloxone, the overdose reversal drug, erases the advantage (Robinson et al., Science Advances 2021). The threshold is real and it is opioid-shaped.
One honest caveat before the tour continues. Human pain testing in redheads is messy and depends on the modality; in the same lidocaine work, sensitivity to cold and heat actually ran higher. The clean, replicated, bedside-relevant facts are the ones above: more volatile anesthetic, less local anesthetic effect, and a mechanism that runs through the opioid system.
Everybody thinks this gene is about hair color. In the skin, MC1R is the switch between brown-black pigment and the red-yellow pigment called pheomelanin, and a broken switch means red. But the receptor does not stop at cosmetics.
In the skin, the red pigment itself is dangerous. Red hair carries up to three times the melanoma risk, and not just from sun. When researchers deleted the red pigment from red-haired mice, melanoma risk dropped, with the damage tracing to oxidative stress from the pigment pathway itself (Mitra et al., Nature 2012). That pigment does oxidative damage in the dark.
In the brain, the same receptor shows up in Parkinson's. In 131,821 Harvard-tracked adults, risk climbed step by step as hair color lightened, redheads at the top of the gradient, and pooled analyses since put their odds roughly 70 percent above everyone else's (Gao et al., Ann Neurol 2009). Mice carrying the redhead variant progressively lose dopamine neurons and prove more vulnerable to the toxins we use to model the disease (Chen et al., Ann Neurol 2017). The neurons at stake live in the substantia nigra, a structure named, literally, for its pigment. A pigment gene, killing dopamine neurons.
Even aging reports to it. In a genome study of thousands of faces, people carrying two variant copies of MC1R read as much as two years older than their birth certificates, independent of sun damage and skin tone (Liu et al., Current Biology 2016).
So here is the bedside translation. If you are a natural redhead: say so to your anesthesiologist, expect your dentist to reach for a second cartridge and ask for it without apology, and keep your dermatology appointments even if you never burn, because your pigment works in the dark. If you are a clinician: budget roughly a fifth more anesthetic agent, and when infiltration fails in a red-haired patient, reach for more drug before you reach for a psychological explanation. The failure has a phenotype.
2. Publication
One paper worth reading, in three sentences.
In the 1980s, researchers enrolled 20,863 Finnish men into a vitamin trial and, almost as an afterthought, wrote down their hair color; a quarter century and 1,982 prostate cancers later, someone finally asked the file a question, and the red-haired men had roughly half the risk of everyone else, hazard ratio 0.46 (Weinstein, Virtamo, Albanes, Br J Cancer 2013;109:747-750, doi 10.1038/bjc.2013.385). Honest cards: the redheads were few, the confidence interval is wide, and the whole cohort smoked, so this is a more hypothesis-generating than fixed scientific fact. What makes it my pick is the economics, because nobody ran a new trial, nobody recruited a single patient, and the marginal cost of the discovery was asking a different question of data that had been sitting in a drawer since the Cold War.
3. Product
This week's pick: sunscreen you will actually reapply. Unsponsored, no affiliate relationship, and obviously not a BellyMD product.
The evidence here is better than most people assume. In the Nambour trial, 1,621 Australian adults were randomized to daily sunscreen or use-it-when-you-feel-like-it, and a decade after the trial ended the daily group had half the melanomas and roughly three quarters fewer invasive ones (Green et al., J Clin Oncol 2011;29:257-263). Modest trial, wide intervals, and still one of the only times a cancer has been prevented in a randomized study with something you can buy at a pharmacy.
Two honest notes. The bottle matters less than the habit, so the right sunscreen is broad-spectrum, SPF 30 or higher, and pleasant enough that you use it daily; EltaMD UV Clear is the dermatology-office workhorse if you want a name. And if you are a redhead, remember what the mouse study showed: sunscreen buys off the ultraviolet half of your risk and does nothing about the pigment working in the dark, which is why the skin check keeps its place on your calendar either way.
4. Person
One person worth following in this space.
David E. Fisher, MD, PhD, chief of dermatology at Massachusetts General Hospital and director of its Cutaneous Biology Research Center. Most labs pick an organ. Fisher picked a receptor and let it drag him across the body: his group produced both the 2012 paper showing red pigment drives melanoma without ultraviolet light and the 2021 paper explaining redhead pain thresholds through opioid tone. That is the same gene, followed honestly for a decade, from skin cancer to pain pharmacology. He is not a social media presence; following him means reading what the lab publishes, and it is worth the effort, because wherever MC1R turns up next, he will already be there.
Red hair is the easy one. It is visible from across a room, it has been sitting in plain sight for two hundred years of modern medicine, and it still took until 2004 to explain why these patients feel the drill. You carry a thousand traits nobody can see from across a room: how you sleep, how you flush, how your gut moves, what the 3 p.m. crash does to you. No chart holds them in one place, so nobody gets to ask the Finnish question of them. That conviction is why we built MeNome, our free tracking app, at menome.belly-md.com. The pattern was never hiding. Nobody was looking.
That's the four. See you next week.
Rick
From BellyMD
I build MGB+, a small supplement line for gut-brain support: Clear, Cool, and Calm, each a magnesium and B-vitamin based formula meant to support the gut-brain axis as part of a broader routine. Structure-function support, not a treatment for any disease. If that is relevant to you, it lives at belly-md.com.
If you want to talk through your own gut-brain picture with me directly, I offer a gut-brain consultation (educational, 500 dollars). Details at belly-md.com.
Not medical advice. This newsletter is for education and does not create a physician-patient relationship. Nothing here is a diagnosis or a prescription. Talk to your own physician before starting, stopping, or combining any medication or supplement, including over-the-counter ones.